Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: A phase I study

Cancer

Volumn 91, Issue 4, 2001, Pages 712-720

  Garufi, Carlo ^a   Dogliotti, Luigi ^b   D'Attino, Rita M ^a   Tampellini, Marco ^b   Aschelter, Anna M ^a   Pugliese, Patrizia ^a   Perrone, Maria ^a   Nisticó, Cecilia ^a   Comis, Silvia ^c   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Rhone Poulenc Rorer   (Italy)

Author keywords

5 fluorouracil; Chronotherapy; Colorectal carcinoma; Irinotecan; Leucovorin; Phase I study

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHRONOTHERAPY; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE;

EID: 0035864978     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010215)91:4<712::AID-CNCR1056>3.0.CO;2-4     Document Type: Article

References (36)

1. Topoisomerase I inhibitors: Topotecan and irinotecan
2. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
3. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
4. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
5. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
6. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil
7. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
8. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer
9. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
10. Chronopharmacology of anticancer agents
11. Cancer chronotherapy
12. Chronomodulated versus fixed-infusion-rate of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
13. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
14. Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice
15. DNA synthesis in human bone marrow is circadian stage dependent
16. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: Evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
17. A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal cancer
18. A Phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer
19. Chronomodulated (chrono) infusion of 5-fluorouracil (5-FU) and 1-folinic acid (FA) in 91 patients (pts) with metastatic colorectal cancer: The Regina Elena Cancer Institute experience
20. Phase II trial of chronomodulated (cm) high dose 5-fluorouracil (5-FU) and l-folinic acid (l-fa) in patients with metastatic colorectal cancer (MCC)
21. The EORTC QLQ-30: A quality of life instrument for use in international clinical trials in oncology
22. Reporting results of cancer treatment
23. Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhea
24. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
25. Addition of oxaliplatin to chronomodulated 5-fluorouracil and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer
26. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
27. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first line chemotherapy in patients with advanced colorectal cancer
28. Escalating dose irinotecan (CPT-11) immediately prior or after 5-fluorouracil (5-FU) 48 hours infusion + leucovorin (LV): Pharmacokinetic and pharmacodynamic interactions in chemotherapy-naive metastatic colorectal cancer patients
29. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
30. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients
31. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
32. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
33. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer
34. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice
35. Circadian changes in irinotecan toxicity in mice
36. Irinotecan (CPT-11) and oxaliplatin (l-OHP) synergistic activity at specific circadian times in tumor-bearing mice